Lead and Peripheral Neuropathy, Computerized Dementia Screening,Buccal Fentanyl, FDA Electronic Surveillance for Side Effects
- Submission
Lead and Peripheral Neuropathy, Computerized Dementia Screening,Buccal Fentanyl, FDA Electronic Surveillance for Side Effects
Exposure to even low levels of lead may be associated with increased risk for peripheral neuropathy. A new computerized test for dementia may be useful for office screening. The FDA recommended against approving the buccal formulation of fentanyl for pain other than that associated with cancer. The FDA has also developed a new electronic surveillance system to identify adverse drug reactions.
Submission | July 4, 2008
